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Abstract
Background: Choice of empirically prescribed antimicrobials for sepsis management depends on epidemiological
factors. The epidemiology of sepsis in Greece was studied in two large-periods.
Methods: Sepsis due to bloodstream infections (BSI) from July 2006 until March 2013 was recorded in a
multicenter study in 46 departments. Patients were divided into sepsis admitted in the emergencies and
hospitalized in the general ward (GW) and sepsis developing after admission in the Intensive Care Unit (ICU). The
primary endpoints were the changes of epidemiology and the factors related with BSIs by multidrug-resistant
(MDR) pathogens; the secondary endpoint was the impact of de-escalation on antimicrobial therapy.
Results: 754 patients were studied; 378 from 2006–2009 and 376 from 2010–2013. Major differences were recorded
between periods in the GW. They involved increase of: sepsis severity; the incidence of underlying diseases; the
incidence of polymicrobial infections; the emergence of Klebsiella pneumoniae as a pathogen; and mortality. Factors
independently related with BSI by MDR pathogens were chronic hemofiltration, intake of antibiotics the last three
months and residence into long-term care facilities. De-escalation in BSIs by fully susceptible Gram-negatives did
not affect final outcome. Similar epidemiological differences were not found in the ICU; MDR Gram-negatives
predominated in both periods.
Conclusions: The epidemiology of sepsis in Greece differs in the GW and in the ICU. De-escalation in the GW is
a safe strategy.
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Background
Bloodstream infections (BSIs) are a significant cause of
mortality especially if they are manifested with signs of
sepsis and septic shock [1, 2]. Initial antimicrobial therapy,
although empirical, has an important impact upon the
survival of patients with sepsis and BSI [3-5]. Since micro-
biology results become available after 48 to 96 hours, ap-
propriate selection of initially administered antimicrobials
depends on factors of epidemiology suggesting both the
most likely pathogen and the probable susceptibility pro-
file. The same applies for patients developing sepsis and
BSI after admission to an Intensive Care Unit (ICU). In
this case, initial choice of antimicrobials is more difficult
since multidrug-resistant (MDR) pathogens predominate
in the nosocomial ICU environment.
Nowadays it is recognized that when initial coverage
with broad-spectrum antimicrobials is administered to
cover all probable pathogens and to improve outcomes,
the chances to provide antimicrobial selection pressure
ending with the predominance of MDR isolates are sig-
nificantly increased [6]. One of the strategies recom-
mended to avoid selection of MDR isolates is antibiotic
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de-escalation [7]. This strategy includes either switching
to a narrower spectrum antimicrobial when the antibio-
gram is available or reducing the number of antibiotics
used. The application of this strategy is nevertheless
limited with a rate varying between 22 and 74% of cases
particularly when this concerns patients with ventilator-
associated pneumonia (VAP) [8–10].
Greece is traditionally regarded as an environment of
high-selection pressure for the emergence of resistant
isolates due to the over-consumption of antimicrobials
both in the community and in the hospitals [11]. The
changing epidemiology of sepsis in Greece may be used
as a prototype for similar environments worldwide suf-
fering by predominance of MDR pathogens. Selection of
empirically administered antimicrobials in critically ill
patients with sepsis relies on the knowledge of the fol-
lowing: a) over-time change of the epidemiology of im-
plicated pathogens; b) epidemiological factors that can
predict implication of MDR pathogens; and c) the out-
come of de-escalation of antimicrobials. To answer these
questions, a prospective multicenter study was conducted
in Greece from 2006 until 2013.
Methods
Study design
This is an ongoing prospective observational study con-
ducted since September 2006 in 46 departments coming
from 31 hospitals in Greece. From these departments,
21 are mixed surgical/medical ICUs; 20 are departments
of internal medicine; and five are departments of general
surgery. The protocol was approved by the Ethics Com-
mittee of each hospital. Written informed consent was
collected from all patients or from first-degree relatives
for patients unable to consent. Patients with community-
acquired sepsis admitted to the general ward or with
hospital-acquired sepsis developing in the ICU at least
48 hours after ICU admission are enrolled in this study.
Participating departments were not obliged to report all
cases of sepsis admitted since the beginning of the
study. Data referring to patients with BSIs due to sep-
sis collected until March 2013 were analyzed in the
current manuscript.
Inclusion criteria were: a) age ≥18 years; b) at least
two signs of the systemic inflammatory response syn-
drome; and c) presence of BSI. Exclusion criteria were:
a) infection by the human immunodeficiency virus; b)
neutropenia defined as less than 1000 neutrophils/mm3
due to causes other than sepsis; c) death of patients be-
fore the results of blood cultures were available.
The following signs of SIRS were considered for study
enrollment [12]: a) core temperature >38°C or <36°C, b)
pco2 < 32 mmHg or more than 20 breaths/min, c) pulse
rate >90/min, and d) white blood cells >12,000/mm3
or <4,000/mm3 or >10% of band forms. Patients were
classified as suffering from sepsis, severe sepsis and septic
shock according to standard definitions [12].
BSI was considered as the isolation of at least one
Gram-negative or Gram-positive or one fungal species
from blood sampled from a peripheral vein. If coagulase-
negative Staphylococcus spp (CoNS) and other common
skin flora were isolated, they were considered as skin
contaminants if they were isolated in a single blood cul-
ture. When CoNS was isolated both from a central and a
peripheral vein with the same antibiogram, it was con-
sidered true pathogen.
When no underlying infection was diagnosed despite in-
tense clinical and radiological work-out, BSI was considered
primary. In all other cases it was considered secondary to
another infection. For the cases of secondary BSIs, diagnosis
of acute pyelonephritis, community-acquired pneumonia,
intraabdominal infections, ventilator-associated pneumonia
and acute bacterial skin and soft tissues infections were done
by standard definitions [13–15].
Only one septic episode for each patient was studied.
Polymicrobial BSI was identified when at least two different
microorganisms were isolated from blood within a 48-h
period. The following information were recorded: demo-
graphics; Acute Physiology and Chronic Health Evaluation
(APACHE) II score; laboratory examinations; source of BSI;
administered antimicrobial agents; isolated pathogens from
the bloodstream and their antibiogram; co-existing diseases;
predisposing conditions; and 28-day outcome expressed as
crude mortality. Prior exposure to an antimicrobial agent
was elaborated both by the patients’ case history and by
monitoring of the prescribed drugs over the last three
months.
For blood culturing, 10 ml of blood was inoculated into
ready-prepared culture vials (bioMérieux, Marcy l’Etoile,
France) and incubated into the Vitek 2 automated system.
The same system reported for identification of microor-
ganisms and for susceptibility testing by measurement of
the minimum inhibitory concentrations (MICs) of antimi-
crobials onto pre-coated microplates. Susceptibility was
reported based on the CLSI susceptibility criteria. For spe-
cies of Staphylococcus aureus susceptibility to methicillin
was defined by the inhibition of growth around a disk of
30 μg of cefoxitin after plating onto Muller-Hinton agar.
Susceptibility of Gram-negative species to colistin was
assessed by a similar way using a 10 μg disk.
Administered antimicrobial therapy was considered ap-
propriate when the isolated microorganism was susceptible
to at least one of the administered antimicrobials. Any
bloodstream isolate resistant to at least three drugs of dif-
ferent classes was considered multidrug-resistant (MDR).
Study end-points
The primary study endpoints were the changes of
epidemiology of BSIs causing sepsis over the 7-year
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time period and the factors related with BSIs by MDR
pathogens.
The secondary study endpoint was the impact of de-
escalation of antimicrobial therapy on the final outcome.
Statistical analysis
Episodes of BSIs were studied into two equal study time
periods; from September 2006 until December 2009 and
from January 2010 until April 2013. In each study period,
patients were divided into two groups: those admitted
with sepsis in the emergency department and who were
hospitalized in the general ward (GW) and into those who
developed sepsis at least 48 hours after ICU admission.
Comparisons between groups were done by the X2 test for
qualitative variables and by the Student’s “t-test” for the
quantitative variables. In order to assess factors related
with BSI by one MDR pathogen, univariate analysis was
done only for the GW group. Those factors with a p value
of significance lower than 0.100 entered as independent
variables into a logistic regression analysis model. Odds
ratios (ORs) and 95% confidence intervals (CI) were
determined.
Only patients in the GW with BSIs by fully susceptible
Gram-negative isolates of both study periods were ana-
lyzed for the secondary endpoint. As such de-escalation
therapy was considered as a switch to a drug class cover-
ing a narrower spectrum of microorganisms. The decision
for de-escalation was made according to the discretion of
the attending physicians. Patients of each study period
were divided into the de-escalation arm and into the non-
de-escalation arm. Survival of each arm was measured by
Kaplan-Meier analysis; comparisons were done by the
log-rank test. Since the study was observational, to as-
sess the impact of sepsis severity on final outcome, for-
ward Cox-logistic regression analysis was done; presence
of severe sepsis/shock, age, gender, history of at least one
underlying disease and de-escalation were entered as inde-
pendent variables in the equation. Hazard ratios (HRs)




Blood sampling was done prior to administration of the
first dose of empirical antimicrobial therapy in 773 out
of 1814 patients (42.9%) screened during the 2006–2009
study period and in 748 out of 1292 patients (57.9%)
screened during the 2010–2013 study period (p < 0.0001
between the two study periods). The study flow-chart is
shown in Figure 1. According to this, a total of 754 cases
of BSIs with sepsis were studied for the primary study
endpoint; 378 BSIs from the 2006–2009 study period;
and 376 BSIs from the 2010–2013 study period; 94 and
129 BSIs respectively met the criteria to be studied for
the impact of de-escalation of antimicrobials on the final
outcome.
Primary end-point
The primary study end-point was the changes of the
characteristics of severe BSIs during the two study pe-
riods. Demographic and clinical characteristics shown in
Table 1 indicate the absence of any differences between
the populations hospitalized in the ICUs. On the con-
trary, major differences were recorded between the two
Figure 1 Study flow-chart. Abbreviations BSI: bloodstream infection; ER: emergency department; ICU intensive care unit; SIRS: systemic
inflammatory response syndrome.
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study periods for patients hospitalized in the GW. These
changes involved mainly an increase of sepsis severity
and of the incidence of underlying diseases from the first
to the second study period but also a reciprocal increase
of mortality. Logistic regression analysis of these changes
revealed that increase of type 2 diabetes mellitus was the
main difference between the two study periods (Table 2).
The distribution of pathogens for patients hospitalized
outside the ICU for sepsis is shown in Figure 2. Polymi-
crobial infections of both Gram-positive and Gram-
negative etiology increased from the first study period to
the second study period. A similar increase has also been
shown for infections caused by Klebsiella pneumoniae.
This change in pathogen distribution was accompanied
by changes in resistance rates. The most frequent isolates
were E.coli and K.pneumoniae. Their resistance patterns
are shown in Figure 3. Regarding E.coli, resistance rates
for 2nd and 3rd generation cephalosporins were increased
from the 2006–2009 period to the 2010–2013 period.
Similar increases were described for K.pneumoniae involv-
ing the great majority of the studied antimicrobials. Pro-
duction of extended-spectrum β-lactamases (ESBL) was
found in 16.4% of Gram-negative isolates of the 2006–
2009 study period and in 27.1% of Gram-negative isolates
of the 2010–2013 study period (p: 0.016). Production of
KPC carbapenemases was found in 7.5% and 14.8% of
Gram-negative isolates respectively (p: 0.031). Resistance
Table 1 Demographic and clinical characteristics of
patients with sepsis and bloodstream infections of the
two study periods
2006-2009 2010-2013 p
Admission in the emergencies and
general ward hospitalization
Male gender (n,%) 120 (49.8) 121 (42.6) 0.114
Age (years, mean ± SD) 70.2 ± 16.6 73.3 ± 15.3 0.034
APACHE II (mean ± SD) 14.33 ± 8.57 17.87 ± 8.27 <0.0001
White blood cell count







Uncomplicated sepsis 152 (62.3) 151 (52.2) 0.022
Severe sepsis/shock 92 (37.7) 138 (47.8)
Underlying type of infection
(n,%)
Acute pyelonephritis 119 (48.8) 148 (51.2)
Community-acquired
pneumonia
19 (7.8) 22 (7.7)
Intrabdominal infections 32 (13.1) 38 (13.1) 0.052
Primary bacteremia 69 (28.3) 71 (24.6)
Soft-tissue infections 3 (1.2) 4 (1.4)
Catheter-related bacteremia 2 (0.8) 6 (2.1)
Underlying diseases (n,%)
Type 2 diabetes mellitus 61 (25.0) 118 (40.8) <0.0001
Chronic heart failure 42 (17.2) 70 (24.2) 0.055
COPD 13 (5.3) 27 (9.3) 0.099
Chronic renal disease 15 (6.1) 32 (11.1) 0.048
Systemic oral corticosteroids 7 (2.9) 15 (5.2) 0.197
Solid tumor malignancy 49 (20.1) 46 (15.9) 0.214
Predisposing conditions (n,%)
Ischemic stroke 33 (13.5) 61 (21.1) 0.023
Dementia 26 (10.7) 20 (6.9) 0.163
Gallstones 29 (11.9) 22 (7.6) 0.105
Renal stones 36 (14.8) 49 (17.0) 0.553
Appropriateness of administered
antibiotics (n,%)
227 (93.0) 233 (91.4) 0.364
Mortality (n,%) 45 (18.4) 95 (32.9) <0.0001
Sepsis developing after ICU admission
Male gender (n,%) 83 (66.9) 51 (61.4) 0.459
Age (years, mean ± SD) 63.6 ± 15.9 61.9 ± 19.67 0.489
APACHE ΙΙ (mean ± SD) 21.57 ± 7.15 20.99 ± 8.16 0.589
White blood cell count







Uncomplicated sepsis 33 (24.6) 19 (21.8) 0.634
Severe sepsis/shock 101 (25.4) 58 (78.2)
Underlying type of
infection (n,%)
Table 1 Demographic and clinical characteristics of
patients with sepsis and bloodstream infections of the
two study periods (Continued)
Ventilator-associated pneumonia 36 (26.9) 29 (33.3)
Intrabdominal infections 1 (0.7) 3 (3.4) 0.034
Primary bacteremia 90 (67.2) 50 (57.5)
Catheter-related bacteremia 7 (5.2) 5 (5.7)
Underlying diseases (n,%)
Type 2 diabetes mellitus 38 (28.4) 20 (30.0) 0.435
Chronic heart failure 40 (29.9) 21 (24.1) 0.441
COPD 41 (30.6) 17 (19.5) 0.085
Chronic renal disease 14 (10.4) 9 (10.3) 1.000
Systemic oral corticosteroids 9 (6.7) 13 (14.9) 0.064
Solid tumor malignancy 14 (10.4) 6 (6.9) 0.474
Predisposing condition (n,%)
Ischemic stroke 30 (22.4) 17 (24.6) 0.728
Multiple injuries 10 (7.5) 10 (14.5) 0.137
Appropriateness of administered
antimicrobials (n,%)
104 (77.6) 62 (71.7) 0.538
Mortality (n,%) 50 (37.3) 40 (45.9) 0.208
Data are expressed as the number of cases (%), except where specified.
Abbreviations: COPD chronic obstructive pulmonary disorder, ICU intensive
care unit.
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of S.aureus to methicillin was 25% for the 2006–2009 iso-
lates and 37.5% for the 2010–2013 isolates (p: 0.447).
These findings generated the question which factors
from the patients’ history are related to a greatest risk
for infection by MDR pathogens among patients in the
GW. Since patients of the two study periods differed in
their demographic characteristics, patients of both pe-
riods were encountered together. To this end, univariate
analysis indicated for a positive relationship with APACHE
II score more than 13 (p: 0.083); history of chronic obstruct-
ive pulmonary disease (p: 0.083); presence of a pig-tail ur-
eteral catheter (p: 0.084); chronic hemofiltration (p: 0.001);
intake of antibiotics the last three months (p: 0.056); and
residence into a long-term care facility (LTCF) (p: 0.011).
Logistic regression analysis was then performed taking into
consideration all these factors as independent variables in
the equation (Table 3). This analysis indicated that the only
factors independently related with BSI by MDR pathogens
were chronic hemofiltration, intake of antibiotics the last
three months and residence into one LTCF.
The distribution of pathogens for patients developing
sepsis after ICU admission is shown in Figure 4. As it
can be seen, infections by S.aureus and by CoNS in-
creased from the 2006–2009 period to the 2010–2013
study periods. Resistance of these species to methicillin
was 95.9% for the 2006–2009 isolates and 100% for the
2010–2013 isolates (p: 1.000). Resistance rates for K.
pneumoniae, A.baumannii and P.aeruginosa that were
the main Gram-negative pathogens did not change be-
tween the two study periods (Figure 5). Production of
ESBL was found in 76.6% of Gram-negative isolates of the
2006–2009 study period and in 71.1% of Gram-negative
isolates of the 2010–2013 study period (p: 0.371). Produc-
tion of KPC carbapenemases was found in 60.9% and
64.9% of Gram-negative isolates respectively (p: 0.431).
Secondary end-point
From the patients enrolled during the first study period,
94 were hospitalized in the GW with BSI by fully sus-
ceptible Gram-negative pathogens; antimicrobials were
Table 2 Logistic regression analysis of factors related
with differences of demographic and clinical
characteristics of patients admitted with sepsis in the
emergencies and hospitalized in the general ward
between the two study periods
OR 95% CI p
Age 1.01 0.99-1.017 0.138
Type of infection 0.97 0.92-1.05 0.663
Presence of severe sepsis/shock 1.16 0.87-1.54 0.318
Type 2 diabetes mellitus 1.63 1.17-2.27 0.004
Chronic renal disease 0.98 0.57-1.69 0.948
Ischemic stroke 1.32 0.89-1.94 0.166
Abbreviations: CI confidence intervals, OR odds ratio.
Figure 2 Distribution of bloodstream pathogens between the two study periods for patients admitted with sepsis in the emergencies
and hospitalized outside the ICU. A) Pathogens are distributed according to Gram stain or fungal species; B) Mixed infections are
presented; C) Distribution of species of Gram (−) bacteria; and D) Distribution of species of Gram (+) cocci. Asterisks indicate statistical
significances between the two study periods. CoNS: coagulase negative Staphylococcus spp.
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de-escalated in 53 patients and non-de-escalated in 41
patients. From the patients enrolled during the second
study period, 129 patients were hospitalized in the GW
with BSI by fully susceptible Gram-negative pathogens;
antimicrobials were de-escalated in 36 patients and non-
de-escalated in 93 patients. Mean ± SD APACHE II of
patients not subjected to de-escalation of antimicrobials
during the period 2006–2009 was 14.56 ± 8.63; it was
13.50 ± 11.51 for patients subjected to de-escalation of an-
timicrobials of the same study period (p: 0.632). Respective
values for the study period 2010–2013 were 18.18 ±
7.28 and 13.04 ± 5.89 (p < 0.0001). Kaplan-Meier ana-
lysis showed no statistical difference in final outcome
between patients subjected and not subjected to de-
escalation of antimicrobials of the first study period
(Figure 6A). Prolonged survival was found for patients
subjected to de-escalation compared to patients not-
subjected to de-escalation of antimicrobials during the
second study period (Figure 6C). However the differences
in APACHE II scores for the second study period, led to
Cox regression analysis after adjustment for disease sever-
ity. Still, no impact of de-escalation on final outcome was
found in any of the two study periods (Figure 6B and
Figure 6D).
The type of administered antimicrobials after the anti-
biogram became known is shown in Table 4 being differ-
ent between patients subjected to de-escalation and not
subjected to de-escalation in both study periods.
Discussion
This study describes the trends of epidemiology of sepsis
arising in the field of BSI both for patients admitted with
sepsis from the ED and hospitalized in the GW and for
patients developing sepsis after ICU admission over a
7-year period in Greece. The main findings are: the
need to hospitalize more severe patients in the GW
over the second study period as reflected by the higher
prevalence of comorbidities and by the increased mor-
tality; the increase of K.pneumoniae as a pathogen and
of the resistance rates of Gram-negative pathogens; the
increase of Gram-positive cocci as pathogens in the
ICU; and the safe application of de-escalation policy.
This is the first multicenter study, to our knowledge,
that provides clinical and microbiological characteristics
of well-documented cases with BSI in two different time
periods comprising patients coming from the commu-
nity and from the ICU. The seven-year period of follow-
up is divided into two equal periods of three years each
i.e. 2006 to 2009 and 2010 to 2013. Similar information
is not provided in any other published manuscript be-
cause published evidence does not come as early as in
2013. Much of the explanation for the differences between
the two study periods relies on the greater frequency of
type 2 diabetes mellitus which is a well-recognized risk fac-
tor for severe bloodstream infections [16]. The shortage for
ICU beds in Greece may also be part of this explanation.
The pathogens responsible for community-acquired BSIs
vary widely between countries [17]. In our study, Gram-
negative microorganisms are the predominant pathogens
for patients with sepsis admitted in the ED in both periods.
Our findings agree with other studies demonstrating that
in these settings E.coli is the most common cause of BSI
[16, 18]; however E.coli pathogens of the second study
period showed increased resistance to 2nd- and 3rd-
generation cephalosporins. Moreover, the incidence of
K.pneumoniae was considerably increased from the
first to the second time period. This increase parallels
Figure 3 Resistance rates of isolates of Escherichia coli and of
Klebsiella pneumoniae of patients admitted with sepsis and
hospitalized outside the ICU for the two study periods. Asterisks
indicate statistical significances between the two study periods.
Table 3 Logistic regression analysis of factors related
with the occurrence of infections by multidrug-resistant
pathogens of patients admitted with sepsis in the
emergencies and hospitalized in the general ward
OR 95% CI p
APACHE II > 13 1.57 0.79-3.09 0.192
History of COPD 2.61 0.78-8.77 0.120
Pigtail ureter catheterization 4.67 0.94-23.23 0.060
Chronic hemofiltration 7.16 1.93-26.54 0.004
Intake of antibiotics the last 3 months 2.48 1.34-4.57 0.004
Residence in one LTCF 4.62 2.12-10.10 <0.0001
Abbreviations: APACHE acute physiology and chronic health evaluation score,
CI confidence intervals, COPD chronic obstructive pulmonary disorder,
LTCF long-term care facility, OR odds ratio.
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Figure 4 Distribution of bloodstream pathogens between the two study periods for patients with sepsis developing after ICU
admission. A) Pathogens are distributed according to Gram stain or fungal species; B) Mixed infections are presented; C) Distribution of species
of Gram (−) bacteria; and D) Distribution of species of Gram (+) cocci. Asterisks indicate statistical significances between the two study periods.
CoNS: coagulase negative Staphylococcus spp.
Figure 5 Resistance rates of isolates of Klebsiella pneumoniae, of Acinetobacter baumannii and of Pseudomonas aeruginosa of patients
developing sepsis after ICU admission of the two study periods.
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Table 4 Antimicrobial treatment in relation to de-escalation policy
Antimicrobial combination Non-de-escalation De-escalation p
2006-2009 study period (n,%)
β-lactamase inhibitors 0 (0) 15 (28.3)
2nd generation cephalosporins 0 (0) 16 (30.2)
3rd generation cephalosporins 6 (14.6) 2 (3.8)
Piperacillin/tazobactam 27 (65.8) 3 (5.6) <0.0001
Carbapanem 3 (.3) 0 (0)
Carbapanem + glycopeptide 5 (12.2) 0 (0)
Ciprofloxacin 0 (0) 17 (32.1)
2010-2013 study period (n,%)
β-lactamase inhibitors 0 (0) 8 (22.2)
2nd generation cephalosporins 0 (0) 15 (41.7)
3rd generation cephalosporins 7 (7.5) 5 (13.9)
Piperacillin/tazobactam 59 (63.4) 2 (5.5) <0.0001
Piperacillin/tazobactam + glycopeptide 9 (9.7) 0 (0)
Carbapanem 10 (10.8) 0 (0)
Carbapanem + glycopeptide 8 (8.6) 0 (0)
Ciprofloxacin 0 (0) 6 (16.7)
Antimicrobials prescribed to patients after culture results and the antibiogram became known to the attending physicians are shown.
Figure 6 Impact of de-escalation on final outcome. Kaplan Meier survival analysis was conducted comparing patients for which antimicrobials
were de-escalated by the attending physicians (Yes, solid line) with those for which antimicrobials were not de-escalated by the attending
physicians (No, dashed line) separately for the study period 2006–2009 (panel A) and for the study period 2010–2013 (panel C). P values
refer to comparisons between patients under de-escalation and patients without de-escalation. Panels B (study period 2006–2009) and D (study
period 2010–2013) refer to forward Cox regression analysis of the impact of de-escalation on the final outcome after adjustment for the presence
of severe sepsis/shock, age, gender and for comorbid illnesses. CI: confidence intervals; HR: hazard ratio.
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the increase in resistance of this pathogen to cephalo-
sporins, quinolones and carbapenems and confirms the
fact that the presence of antimicrobial resistant bac-
teria increases the total burden of disease [19]. This
trend in resistance is alarming considering the known
phenomenon of the presence of Klebsiella- producing
carbapenemase (KPC) in Greek hospitals [20]. The sig-
nificant increase in resistance pattern of both E.coli
and K.pneumoniae pathogens probably reflects the rise
of ESBL in the community [18] and the ability of these
two species of Enterobacteriacae to transmit their re-
sistance genes through plasmids [21].
Early administration of antimicrobials active on the impli-
cated pathogens is the key to appropriate management. The
current study provides salient information about the choice
of antimicrobials. Information coming from the patients’
history about recent contact with a health-care-associated
setting like the conduct of chronic hemofiltration and resi-
dence in a long-term care facility and the recent intake of
antimicrobials should guide initial treatment towards broad-
spectrum antimicrobial coverage. The current study also
supports the use of a de-escalation policy for sepsis caused
by fully susceptible Gram-negative pathogens. De-escalation
to narrower spectrum antimicrobials does not impact final
outcome. It may even be suggested that this policy led
to survival benefit in the second study period. However,
the proportion of patients de-escalated in the second
study period was decreased compared with the first
study period. The study was not interventional for the
implementation of the de-escalation but this was a
choice of the attending physicians. It may be hypothe-
sized that the decrease of proportion of de-escalated
patients may be linked with a feeling of physicians that
antimicrobial resistance increase over-time and a subse-
quent fear for the de-escalation strategy. This is one of
few studies on the impact of de-escalation policy in
sepsis. In a recent publication, Garnacho-Montero et al.
[22] followed-up prospectively 712 admissions due to
severe sepsis in an ICU; de-escalation performed in 219
patients was a protective factor against both 30-day and
90-day mortality.
The situation of Greek ICUs for patients with sepsis de-
veloping after ICU admission are similar to other Euro-
pean countries regarding demographics and mortality [19,
23]. However it should be underscored that MDR
Gram-negative species of K.pneumoniae, A.baumannii
and P.aeruginosa predominate although a significant
increase of BSIs by Gram-positive cocci mainly of spe-
cies of S.aureus and of CoNS is recorded between the
two study periods. These findings suggest that initial
empirical therapy of sepsis developing after ICU admis-
sion should contain anti-Gram-positive coverage and that
selection of anti-Gram-negative coverage should rely on
the local resistance surveillance.
Conclusion
The findings of the current study suggest that the epi-
demiology of sepsis in Greece is different for patients
admitted in the ED and for patients who develop sepsis
after ICU admission. Although Gram-negative bacterial
predominate in both settings, resistance profiles are
quite different and they are driven by the history of anti-
microbial consumption and the exposure to health-care-
associated settings. Application of de-escalation is a safe
strategy when susceptible pathogens are involved.
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